Organization
Elpiscience Biopharma
4 clinical trials
1 abstract
Clinical trial
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 Administered as a Single Agent in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-01
Clinical trial
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion, Phase 1 Study of ES014 in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Withdrawn, Estimated PCD: 2026-04-30
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of ES002023 in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Abstract
Preclinical characterization of a novel anti-CD39/TGFβ-trap bispecific antibody that aims to modulate tumor microenvironment.Org: Elpiscience Biopharma, Inc., Elpiscience Biopharma, Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Medical Oncology, Shanghai Chest Hospital, Jiao Tong University,